Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

VitaNova Life Sciences (YJGJ) EBT (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed EBT for 9 consecutive years, with $99290.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 63.37% year-over-year to $99290.0, compared with a TTM value of $1.3 million through Oct 2025, up 394.22%, and an annual FY2025 reading of $1.2 million, up 485.37% over the prior year.
  • EBT was $99290.0 for Q4 2025 at VitaNova Life Sciences, up from -$32440.0 in the prior quarter.
  • Across five years, EBT topped out at $1.1 million in Q2 2025 and bottomed at -$45414.0 in Q3 2024.
  • Average EBT over 5 years is $78194.0, with a median of $2367.5 recorded in 2022.
  • The sharpest move saw EBT plummeted 1236.22% in 2023, then skyrocketed 5408.73% in 2024.
  • Year by year, EBT stood at $15009.0 in 2021, then crashed by 82.67% to $2601.0 in 2022, then tumbled by 436.6% to -$8755.0 in 2023, then soared by 794.17% to $60775.0 in 2024, then surged by 63.37% to $99290.0 in 2025.
  • Business Quant data shows EBT for YJGJ at $99290.0 in Q4 2025, -$32440.0 in Q3 2025, and $1.1 million in Q2 2025.